{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009282","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.375598+00:00","generated_at":"2026-06-15T04:26:37.336580+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC","bullets":["Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.","No dose-related increases in adverse events; neutropenia consistent with palbociclib plus endocrine therapy profile.","Partial responses observed in 5 patients (1 confirmed, 4 unconfirmed); clinical benefit rate 42% (5/12 CBR-eligible).","59% of patients remain on treatment as of March 8, 2023 data cut-off; enrollment ongoing toward ~45 patients.","OP-1250 showed favorable PK: 8-day half-life, dose-proportional exposure, no effect on palbociclib levels."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009282","json":"https://secwatch.observer/filing/0001558370-23-009282.json","markdown":"https://secwatch.observer/filing/0001558370-23-009282.md","text":"https://secwatch.observer/filing/0001558370-23-009282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023009282/0001558370-23-009282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023009282/olma-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:26:37.336580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}